Why the study?
Does switching from ticagrelor to clopidogrel affect the risk of ischemic events and safety in patients with STEMI undergoing successful PCI?
Does switching from ticagrelor to clopidogrel affect the risk of ischemic events and safety in patients with STEMI undergoing successful PCI?
In real-world Chinese STEMI patients undergoing successful PCI, switching from ticagrelor to clopidogrel may be safe but is associated with a higher risk of ischemic events compared to continuing ticagrelor.
De-escalation-associated ischemic risk warrants caution in real-world STEMI PCI; leaves open need for RCTs to confirm versus continued ticagrelor.
Switching from ticagrelor to clopidogrel is very common in patients with STEMI in China. De-escalation might be safe but associated with high risk of ischemic events as compared to ticagrelor.
No takes yet. Share an insight, caveat, or question.
Li et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: